Page last updated: 2024-09-04

docetaxel anhydrous and Urinary Bladder Neoplasms

docetaxel anhydrous has been researched along with Urinary Bladder Neoplasms in 102 studies

Research

Studies (102)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	6 (5.88)	18.2507
2000's	31 (30.39)	29.6817
2010's	35 (34.31)	24.3611
2020's	30 (29.41)	2.80

Authors

Authors	Studies
Grobet-Jeandin, E; Pinar, U; Rouprêt, M	1
Black, PC; Roumiguié, M	1
Ando, R; Banno, R; Etani, T; Hamamoto, S; Iida, K; Isobe, T; Kawai, N; Kubota, H; Nagai, T; Naiki, T; Naiki-Ito, A; Noda, Y; Nozaki, S; Shimizu, N; Sugiyama, Y; Tomiyama, N; Yasui, T	1
Hikita, K; Honda, M; Iwamoto, H; Kawamoto, B; Morizane, S; Shimizu, R; Takenaka, A; Teraoka, S; Yamaguchi, N; Yumioka, T	1
Bamias, A; Bell-McGuinn, KM; Castellano, D; de Wit, R; Drakaki, A; Fléchon, A; Gao, L; Lee, JL; Long, A; Matsubara, N; Necchi, A; Petrylak, DP; Powles, T; Sternberg, CN; van der Heijden, MS; Walgren, RA; Yu, EY; Zimmermann, AH	1
Clark, PE; Meeks, JJ; Sexton, WJ	1
Dewnani, K; diZerega, GS; Kates, M; Lamm, DL; Mansour, AM; Marin, A; Maulhardt, H; Shore, N; Verco, J; Verco, S; Wendt, A	1
Kumar, S; Pareek, T; Parmar, K; Sharma, AP	1
Gellhaus, PT; McElree, IM; Mott, SL; Nepple, KG; O'Donnell, MA; Packiam, VT; Steinberg, RL	1
Gellhaus, PT; Martin, AC; McElree, IM; Mott, SL; Nepple, KG; O'Donnell, MA; Packiam, VT; Richards, J; Steinberg, RL	1
Baltezor, M; diZerega, G; Marin, A; Maulhardt, H; Verco, S	1
Kavoussi, M; Nasrallah, AA; Williams, SB	1
Chevuru, PT; McElree, IM; Mott, SL; O'Donnell, MA; Packiam, VT; Steinberg, RL	1
Araki, M; Kawada, T; Pradere, B; Shariat, SF; Yanagisawa, T	1
O'Donnell, MA; Packiam, VT; Steinberg, RL	1
Abbosh, P; Bell, S; Bukavina, L; Correa, AF; Kutikov, A; Magee, DE; Packiam, VT; Smaldone, M; Uzzo, R	1
Carducci, M; Chu, X; Crispen, P; Daneshmand, S; Hahn, N; Kates, M; Packiam, VT; Pietzak, E; Porten, S; Shevrin, DH; Smith, A; Wagner, LI; Westerman, ME; Williams, SB	1
Bree, K; Davaro, F; Dinney, CP; Kamat, AM; Li, R; McElree, IM; Navai, N; O'Donnell, MA; Packiam, VT; Steinberg, RL; Tan, WS	1
Campbell, M; Castellano, D; Duran, I; Lee, JL; Loriot, Y; Mamtani, R; Matsangou, M; Matsubara, N; Petrylak, DP; Powles, T; Rosenberg, JE; Sonpavde, GP; Vulsteke, C; Wu, C	1
Carvalho, FLF; Clinton, TN; Feldman, A; Hirsch, M; Kibel, AS; Melnick, K; Mossanen, M; Mott, SL; Mouw, KW; O'Donnell, MA; Preston, MA; Rizzo, N; Salari, K; Steele, GS; Wszolek, M; Wu, CL; Yim, K; Zafar, A	1
Akapame, S; Banek, S; Burgess, EF; Deprince, K; Guadalupi, V; Houede, N; Huddart, RA; Kean, Y; Ku, JH; Loriot, Y; Matsubara, N; Mukhopadhyay, S; Park, SH; Siefker-Radtke, AO; Stone, NL; Tran, B; Triantos, S; Valderrama, BP	1
Barry, E; Bivalacqua, TJ; Daniels, MJ; Kates, M; Milbar, N; Sankin, A; Schoenberg, M	1
Bajorin, D; Bellmunt, J; Enokida, H; Frenkl, T; Fujimoto, K; Fukasawa, S; Imai, K; Nishimura, K; Nishiyama, H; Perini, R; Sassa, N; Shimamoto, T; Takahashi, K; Tanaka, Y; Yamamoto, Y; Yokoyama, M	1
Brooks, NA; O'Donnell, MA	1
Bivalacqua, TJ; Brooks, N; Crump, T; Daniels, MJ; DeWolf, WC; Hyndman, ME; Kamat, AM; Kates, M; Lamm, DL; Mott, SL; Nagaraju, S; Nepple, KG; O'Donnell, MA; Rao, MY; Steinberg, RL; Thomas, LJ; Vitale, A; Wang, J	1
Bao, X; Fu, S; Huang, Y; Li, C; Li, H; Li, N; Luan, T; Wang, H; Wang, J	1
Witjes, JA	1
Babjuk, M	1
Afzal, U; Anders, N; Babu, T; Baras, A; Bivalacqua, TJ; Date, AA; Ensign, LM; Hanes, J; He, P; Kanvinde, P; Kates, M; Rudek, M; Yoshida, T	1
Bivalacqua, TJ; Brooks, N; Crump, T; DeWolf, WC; Hyndman, ME; Kamat, AM; Kates, M; Lamm, DL; Mott, SL; Nepple, KG; O'Donnell, MA; Packiam, VT; Steinberg, RL; Thomas, LJ; Vitale, A; Wang, J	1
Chung, JI; Hwang, H; Kim, TS; Noh, GH	1
Deshpande, I; Nitiyanandan, R; Pavan Grandhi, TS; Potta, T; Rege, K	1
Alekseev, B; Bamias, A; Bell-McGuinn, KM; Castellano, D; Chi, KN; Cicin, I; Coskun, HS; de Wit, R; Del Muro, XG; Drakaki, A; Fléchon, A; Géczi, L; Hamid, O; Harputluoglu, H; Hegemann, M; Hussain, S; Laestadius, F; Lee, JL; Liepa, AM; Matsubara, N; Necchi, A; Nishiyama, H; Ou, YC; Peer, A; Percent, IJ; Petrylak, DP; Powles, T; Rodriguez-Vida, A; Safina, S; Semenov, A; Sternberg, CN; Su, WP; Tortora, G; Tucci, M; van der Heijden, MS; Walgren, RA; Widau, RC; Yu, EY; Zimmermann, AH	1
J Pelletier, D; Liu, V; O'Donnell, M; Stone, MS	1
Bongiorno, C; Dahm, P; Gartlehner, G; Hwang, EC; Jung, JH; Kahlmeyer, A; Kunath, F; Narayan, V; Patel, N; Risk, MC; Skoetz, N	1
Gschwend, JE; Horn, T; Maisch, P; Retz, M; von Amsberg, G	1
Abate-Shen, C; Benson, M; Delto, JC; Kobayashi, T; McKiernan, J	1
Carles, J; Maldonado, X; Morales-Barrera, R; Morote, J; Nuñez, I; Suárez, C; Valverde, C	1
Eberhart, C; Goldberg, MF; Hsu, AW; Montaner, S; Sodhi, A	1
Guo, J; Sun, C; Wang, C; Xu, K; Xu, S	1
Hashimoto, Y; Hatakeyama, S; Imai, A; Koie, T; Ohyama, C; Tobisawa, Y; Yamamoto, H; Yoneyama, T	1
Chiong, E; Kang, ET; Lu, S; Mahendran, R; Neoh, KG	1
Cheng, S; Cheon, P; Chow, E; Chow, R; DeAngelis, C; Emmenegger, U; Giotis, A; Lowe, J; McDonald, R; Pasetka, M; Pulenzas, N; Rowbottom, L; Stinson, J; Thavarajah, N	1
Catino, A; De Ceglie, A; Galetta, D; Logroscino, A; Misino, A; Natalicchio, MI; Simone, G	1
Chan, A; De Guzman Langit, MR; Fong, W; Lim, ST; Lim, TA; Song, M; Tang, T; Tay, K	1
Hwang, IG; Kim, YS; Lee, J; Lee, SC; Lee, SI; Lim, HY; Park, S; Park, SH; Sun, JM	1
Albany, C; Sonpavde, G	1
Nepple, KG; O'Donnell, MA; Steinberg, RL; Thomas, LJ; Velaer, KN	1
Bellmunt, J; Sonpavde, G	1
An, X; Cao, Y; Chen, T; Deng, Y; Han, H; Shi, Y; Teng, X; Xue, C; Yang, W; Zhou, F	1
Barlow, LJ; Benson, MC; McKiernan, JM	2
Barlow, L; Benson, M; McKiernan, J; Sawczuk, I	1
Barlow, LJ; Benson, MC; Desai, M; Laudano, MA; McKiernan, JM; Murphy, AM; Petrylak, DP	1
Konety, BR	1
Chade, DC; Dalbagni, G; Karakiewicz, PI; Scherr, DS; Shariat, SF	1
Burt, H; Jackson, J; Tsallas, A	1
Brooks, DE; Burt, HM; Chafeeva, I; Gleave, ME; Heller, L; Heller, M; Matsui, Y; Mugabe, C; So, AI; Zeisser-Labouèbe, M	1
Baker, JH; Brooks, DE; Burt, HM; Gleave, ME; Liggins, R; Manisali, I; Matsui, Y; Minchinton, AI; Mugabe, C; So, AI	1
Flaig, TW; Li, Y; Su, LJ; Yang, X	1
Androulakis, N; Boukovinas, I; Constantinides, CA; Georgoulias, V; Karampeazis, A; Kentepozidis, N; Kostakopoulos, A; Kotsakis, A; Markos, V; Mavroudis, D; Papakotoulas, P; Polyzos, A; Samonis, G; Vardakis, N; Ziras, N	1
Kanekura, T; Kawai, K; Matsushita, S; Mera, K; Yonekura, K	1
Baker, JH; Brooks, DE; Burt, HM; Fazli, L; Gleave, ME; Jackson, JK; Liggins, RT; Minchinton, AI; Mugabe, C; Raven, PA; So, AI	1
Gordian, E; Ramachandran, K; Singal, R	1
Abe, Y; Kusunose, H; Muto, M; Nagura, H; Namima, T; Satake, Y; Tagami, K; Takeuchi, A; Tanda, S	1
Barlow, LJ; Benson, MC	1
André, T; Culine, S; Epaud, C; Gligorov, J	1
Chikazawa, M; Fukata, S; Inoue, K; Shuin, T; Yoshikawa, C	1
Allen, HJ; Baker, C; Bosserman, LD; Chapman, Y; Figlin, RA; Gitlitz, BJ; Patel, R; Sanchez, JD; Shapiro, RM	1
Arai, Y; Hoshi, S; Itoh, A; Ohyama, C; Okada, Y; Ono, K; Saito, S; Satoh, M; Sohma, F; Takeda, A; Yamashita, S; Yamato, T	1
Itoh, S; Mitsuhata, N; Watanabe, Y	1
Arai, Y; Habuchi, T; Horikawa, Y; Hoshi, S; Inoue, T; Kato, T; Matsuura, S; Ohyama, C; Saito, S; Sato, K; Satoh, S; Togashi, H; Tsuchiya, N	1
Becht, C; Bleuse, JP; Culine, S; Cupissol, D; Fabbro, M; Gourgou, S; Guillemare, C; Lotz, V; Romieu, G	1
Bamias, A; Deliveliotis, C; Dimopoulos, MA; Gika, D; Karayiannis, A; Pantazopoulos, D; Varkarakis, I; Zervas, I	1
Bamias, A; Bozas, G; Dimopoulos, MA; Efstathiou, E; Gika, D; Hamilos, G; Kakoyiannis, C; Kastritis, E; Moulopoulos, LA; Papadimitriou, C; Zorzou, MP	1
Artz, A; Ryan, C; Stadler, WM; Vogelzang, NJ; Zimmerman, T	1
Fukata, S; Furihata, M; Inoue, K; Karashima, T; Kawada, C; Kurabayashi, A; Nomura, A; Ohtsuki, Y; Shuin, T	1
Ennist, DL; Ganesh, S; Ge, Y; Mina, M; Ramesh, N; Reddy, PS; Yu, DC; Zhu, M	1
Canil, C; Chi, KN; Moore, M; Murray, RN; Tinker, A; Winquist, E	1
Azuma, K; Hashine, K; Miura, N; Numata, K; Sumiyoshi, Y	1
Benson, MC; Desai, M; Goetzl, M; Masson, P; McKiernan, JM; Murphy, AM; Olsson, CA; Petrylak, DP	1
Adam, L; Brown, G; Dinney, CP; Kassouf, W; Luongo, T	1
Calabrò, F; Sternberg, CN	1
Aerts, R; De Boeck, G; De Bruijn, EA; Dumez, H; Guetens, G; Maes, RA; Martens, M; Selleslach, J; van Oosterom, AT	1
Engelmann, UH; Heidenreich, A; Ohlmann, CH; Ozgür, E; Pfister, D; Sahi, D; Thüer, D	1
Burks, T; Chaudhary, UB; Curry, N; Sawhney, R	1
Braguer, D; Briand, C; Carles, G; Garcia, P	1
Cox, C; Miller, A; Niell, H; Rangel, C	1
Antoine, EC; Khayat, D	1
Orel, NF	1
Bateman, AC; Cook, T; Dunsford, ML; Mead, GM; Tung, K	1
Anagnostopoulos, A; Aravantinos, G; Bakoyannis, C; Bamias, A; Deliveliotis, C; Dimopoulos, MA; Fountzilas, G; Georgoulias, V; Giannopoulos, A; Karayannis, A; Kosmidis, P; Kyriakakis, Z; Moulopoulos, LA; Pantazopoulos, D; Papadimitriou, C; Varkarakis, I; Zervas, A	1
Akaza, H; Hattori, K	1
Aspropotamitis, A; Athanassiou, A; Dimitriadis, M; Halikia, A; Karvounis, N; Pectasides, D; Visvikis, A	1
Malkowicz, SB; Vaughn, DJ	1
Arakawa, S; Hara, I; Hara, S; Kamidono, S; Miyake, H	1
Carles, J; Climent, MA; Garcia del Muro, X; Germá, JR; Gumá, J; Marcuello, E; Maroto, P; Parra, MS; Paz-Ares, L; Tisaire, JL	1
Athanassiou, A; Bountouroglou, N; Glotsos, J; Karvounis, N; Kouloubinis, A; Mitakidis, N; Pectasides, D; Ziras, N	1
Brandl, M; Burger, AM; Fiebig, HH; Massing, U; Moog, R; Schubert, R; Schüler, J; Unger, C	1
Culine, S	1
Chen, Y; Dilley, J; Li, Y; Ramesh, N; Working, P; Yu, DC; Zhang, J	1

Reviews

17 review(s) available for docetaxel anhydrous and Urinary Bladder Neoplasms

Article	Year
Local administration of large surface area microparticle docetaxel to solid carcinomas induces direct cytotoxicity and immune-mediated tumoricidal effects: preclinical and clinical studies. Drug delivery and translational research, 2023, Volume: 13, Issue:2 Topics: Animals; Antineoplastic Agents; Carcinoma, Transitional Cell; Cell Line, Tumor; Docetaxel; Humans; Mice; Tumor Microenvironment; Urinary Bladder Neoplasms	2023
Sequential intravesical gemcitabine and docetaxel therapy in patients with nonmuscle invasive bladder cancer: a systematic review and meta-analysis. Current opinion in urology, 2023, 05-01, Volume: 33, Issue:3 Topics: Adjuvants, Immunologic; Administration, Intravesical; BCG Vaccine; Docetaxel; Gemcitabine; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms	2023
Combination Intravesical Therapy. The Urologic clinics of North America, 2020, Volume: 47, Issue:1 Topics: Adjuvants, Immunologic; Administration, Intravesical; Antimetabolites, Antineoplastic; Antineoplastic Agents; BCG Vaccine; Deoxycytidine; Docetaxel; Drug Therapy, Combination; Gemcitabine; Humans; Neoplasm Invasiveness; Salvage Therapy; Treatment Outcome; Urinary Bladder Neoplasms	2020
Pembrolizumab monotherapy versus chemotherapy for treatment of advanced urothelial carcinoma with disease progression during or following platinum-containing chemotherapy. A Cochrane Rapid Review. The Cochrane database of systematic reviews, 2018, 07-23, Volume: 7 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Disease Progression; Docetaxel; Humans; Paclitaxel; Quality of Life; Taxoids; Urinary Bladder Neoplasms; Vinblastine	2018
[50 years of systemic therapy of urinary bladder cancer]. Aktuelle Urologie, 2019, Volume: 50, Issue:4 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carcinoma, Transitional Cell; Clinical Trials as Topic; CTLA-4 Antigen; Docetaxel; Humans; Immunotherapy; Neoplasm Metastasis; Programmed Cell Death 1 Receptor; Randomized Controlled Trials as Topic; Survival Rate; Urinary Bladder Neoplasms; Vinblastine	2019
Docetaxel for the treatment of bladder cancer. Expert opinion on investigational drugs, 2015, Volume: 24, Issue:12 Topics: Antineoplastic Agents; Carcinoma, Transitional Cell; Docetaxel; Humans; Neoplasm Metastasis; Randomized Controlled Trials as Topic; Salvage Therapy; Taxoids; Urinary Bladder Neoplasms	2015
Experience with Sequential Intravesical Gemcitabine and Docetaxel as Salvage Therapy for Non-Muscle Invasive Bladder Cancer. Current urology reports, 2016, Volume: 17, Issue:5 Topics: Administration, Intravesical; Cystectomy; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Salvage Therapy; Taxoids; Urinary Bladder Neoplasms	2016
Bladder cancer: Angiogenesis as a therapeutic target in urothelial carcinoma. Nature reviews. Urology, 2016, Volume: 13, Issue:6 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Delivery Systems; Humans; Neovascularization, Pathologic; Ramucirumab; Randomized Controlled Trials as Topic; Taxoids; Urinary Bladder Neoplasms; Urothelium	2016
Update on intravesical agents for non-muscle-invasive bladder cancer. Immunotherapy, 2010, Volume: 2, Issue:3 Topics: Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Combined Modality Therapy; Cystectomy; Docetaxel; Humans; Mitomycin; Taxoids; Treatment Outcome; Urinary Bladder Neoplasms	2010
[Successful chemotherapy with a docetaxel regimen for primary signet-ring cell carcinoma of the urinary bladder-a case report]. Gan to kagaku ryoho. Cancer & chemotherapy, 2012, Volume: 39, Issue:11 Topics: Antineoplastic Agents; Carcinoma, Signet Ring Cell; Combined Modality Therapy; Docetaxel; Humans; Male; Middle Aged; Neoplasm Invasiveness; Taxoids; Tomography, X-Ray Computed; Urinary Bladder Neoplasms	2012
Experience with newer intravesical chemotherapy for high-risk non-muscle-invasive bladder cancer. Current urology reports, 2013, Volume: 14, Issue:2 Topics: Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Carcinoma, Transitional Cell; Deoxycytidine; Docetaxel; Doxorubicin; Gemcitabine; Humans; Mitomycin; Paclitaxel; Taxoids; Thiotepa; Treatment Failure; Urinary Bladder Neoplasms	2013
State-of-the-art management of metastatic disease at initial presentation or recurrence. World journal of urology, 2006, Volume: 24, Issue:5 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Disease-Free Survival; Docetaxel; Gemcitabine; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Taxoids; Urinary Bladder Neoplasms	2006
[The role of new drugs in the treatment of locally advanced urothelial tumors of the bladder]. Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 1998, Volume: 2 Suppl 1 Topics: Antineoplastic Agents; Carcinoma, Transitional Cell; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasm Invasiveness; Paclitaxel; Taxoids; Urinary Bladder Neoplasms	1998
[Taxotere in various solid tumors]. Voprosy onkologii, 1998, Volume: 44, Issue:5 Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Melanoma; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Prostatic Neoplasms; Sarcoma; Skin Neoplasms; Soft Tissue Neoplasms; Taxoids; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms	1998
[New combination chemotherapy in urological cancers]. Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Gemcitabine; Humans; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Male; Methotrexate; Paclitaxel; Prostatic Neoplasms; Taxoids; Testicular Neoplasms; Urinary Bladder Neoplasms; Vinblastine	2000
Recent advances in bladder cancer chemotherapy. Cancer investigation, 2001, Volume: 19, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoadjuvant Therapy; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Urinary Bladder Neoplasms	2001
The present and future of combination chemotherapy in bladder cancer. Seminars in oncology, 2002, Volume: 29, Issue:3 Suppl 9 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Gemcitabine; Glutamates; Guanine; Humans; Methotrexate; Paclitaxel; Pemetrexed; Taxoids; Urinary Bladder Neoplasms; Vinblastine	2002

Trials

22 trial(s) available for docetaxel anhydrous and Urinary Bladder Neoplasms

Article	Year
Exposure-response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy. British journal of clinical pharmacology, 2022, Volume: 88, Issue:7 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Docetaxel; Humans; Platinum; Ramucirumab; Urinary Bladder Neoplasms	2022
Phase 1/2 Trial Results of a Large Surface Area Microparticle Docetaxel for the Treatment of High-Risk Nonmuscle-Invasive Bladder Cancer. The Journal of urology, 2022, Volume: 208, Issue:4 Topics: Administration, Intravesical; BCG Vaccine; Docetaxel; Humans; Immune Checkpoint Inhibitors; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Treatment Outcome; Tumor Microenvironment; Urinary Bladder Neoplasms	2022
EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma. Annals of oncology : official journal of the European Society for Medical Oncology, 2023, Volume: 34, Issue:11 Topics: Antibodies, Monoclonal; Carcinoma, Transitional Cell; Docetaxel; Humans; Urinary Bladder Neoplasms	2023
Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma. The New England journal of medicine, 2023, Nov-23, Volume: 389, Issue:21 Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Docetaxel; Humans; Immune Checkpoint Inhibitors; Receptors, Fibroblast Growth Factor; Urinary Bladder Neoplasms	2023
Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial. International journal of clinical oncology, 2020, Volume: 25, Issue:1 Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Docetaxel; Female; Humans; Japan; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Rate; Treatment Outcome; Urinary Bladder Neoplasms; Urologic Neoplasms; Vinblastine	2020
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial. Lancet (London, England), 2017, Nov-18, Volume: 390, Issue:10109 Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Disease-Free Survival; Docetaxel; Double-Blind Method; Female; Humans; Internationality; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Proportional Hazards Models; Ramucirumab; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome; Urinary Bladder Neoplasms	2017
A Phase II Study of Weekly Docetaxel as Second-Line Chemotherapy in Patients With Metastatic Urothelial Carcinoma. Clinical genitourinary cancer, 2016, Volume: 14, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Proportional Hazards Models; Salvage Therapy; Taxoids; Treatment Outcome; Urinary Bladder Neoplasms	2016
A single-institution experience with induction and maintenance intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to bacille Calmette-Guérin therapy. BJU international, 2009, Volume: 104, Issue:8 Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antineoplastic Agents; BCG Vaccine; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Retrospective Studies; Risk Factors; Taxoids; Treatment Outcome; Urinary Bladder Neoplasms	2009
Long-term clinical outcomes of a phase I trial of intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to standard intravesical therapy. Urology, 2010, Volume: 75, Issue:1 Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Transitional Cell; Disease-Free Survival; Docetaxel; Female; Follow-Up Studies; Humans; Male; Middle Aged; Taxoids; Time Factors; Treatment Failure; Urinary Bladder Neoplasms	2010
Chemotherapy with gemcitabine, cisplatin, and docetaxel in the treatment for patients with muscle-invasive bladder cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG). Cancer chemotherapy and pharmacology, 2012, Volume: 69, Issue:2 Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Muscles; Nausea; Neoplasm Invasiveness; Neoplasm Staging; Neutropenia; Taxoids; Thrombocytopenia; Treatment Outcome; Urinary Bladder Neoplasms	2012
A phase II study of gemcitabine and docetaxel therapy in patients with advanced urothelial carcinoma. Cancer, 2003, Nov-01, Volume: 98, Issue:9 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Male; Middle Aged; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome; Urinary Bladder Neoplasms	2003
Reducing the time interval between cycles using standard doses of docetaxel and lenogastrim support: a feasibility study. Cancer, 2004, Jul-01, Volume: 101, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Taxoids; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms	2004
The outcome of elderly patients with advanced urothelial carcinoma after platinum-based combination chemotherapy. Annals of oncology : official journal of the European Society for Medical Oncology, 2005, Volume: 16, Issue:2 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Deoxycytidine; Docetaxel; Doxorubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Infections; Male; Methotrexate; Middle Aged; Neutropenia; Prognosis; Survival Analysis; Taxoids; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine	2005
A phase II trial of sequential chemotherapy with docetaxel and methotrexate followed by gemcitabine and cisplatin for metastatic urothelial cancer. American journal of clinical oncology, 2005, Volume: 28, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Kidney Neoplasms; Kidney Pelvis; Male; Methotrexate; Middle Aged; Survival Analysis; Taxoids; Urinary Bladder Neoplasms; Urothelium	2005
A phase I dose finding study of cisplatin, gemcitabine, and weekly docetaxel for patients with advanced transitional cell cancer. American journal of clinical oncology, 2006, Volume: 29, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Infusions, Intravenous; Maximum Tolerated Dose; Middle Aged; Taxoids; Urinary Bladder Neoplasms	2006
Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Jul-01, Volume: 24, Issue:19 Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Transitional Cell; Docetaxel; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Taxoids; Urinary Bladder Neoplasms	2006
Docetaxel and gemcitabine combination therapy in advanced transitional cell carcinoma of the urothelium: results of a phase II and pharmacologic study. Anti-cancer drugs, 2007, Volume: 18, Issue:2 Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cell Survival; Deoxycytidine; Docetaxel; Erythrocytes; Female; Gemcitabine; Humans; Male; Middle Aged; Taxoids; Urinary Bladder Neoplasms; Urothelium	2007
Severe pulmonary toxicity in patients treated with a combination of docetaxel and gemcitabine for metastatic transitional cell carcinoma. Annals of oncology : official journal of the European Society for Medical Oncology, 1999, Volume: 10, Issue:8 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Docetaxel; Dyspnea; Fatal Outcome; Gemcitabine; Humans; Lung; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Severity of Illness Index; Taxoids; Treatment Outcome; Urinary Bladder Neoplasms	1999
Docetaxel and cisplatin combination chemotherapy in advanced carcinoma of the urothelium: a multicenter phase II study of the Hellenic Cooperative Oncology Group. Annals of oncology : official journal of the European Society for Medical Oncology, 1999, Volume: 10, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Docetaxel; Female; Follow-Up Studies; Greece; Humans; Linear Models; Lymphatic Metastasis; Male; Middle Aged; Paclitaxel; Remission Induction; Severity of Illness Index; Survival Rate; Taxoids; Treatment Outcome; Urinary Bladder Neoplasms; Urologic Neoplasms; Urothelium	1999
Chemotherapy with cisplatin, epirubicin and docetaxel in transitional cell urothelial cancer. Phase II trial. European journal of cancer (Oxford, England : 1990), 2000, Volume: 36, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Docetaxel; Epirubicin; Female; Humans; Male; Middle Aged; Paclitaxel; Survival Analysis; Taxoids; Urinary Bladder Neoplasms	2000
Phase II multicentre study of docetaxel plus cisplatin in patients with advanced urothelial cancer. British journal of cancer, 2002, Feb-01, Volume: 86, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms; Urologic Neoplasms; Urothelium	2002
Weekly chemotherapy with docetaxel, gemcitabine and cisplatin in advanced transitional cell urothelial cancer: a phase II trial. Annals of oncology : official journal of the European Society for Medical Oncology, 2002, Volume: 13, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Taxoids; Urinary Bladder Neoplasms	2002

Other Studies

63 other study(ies) available for docetaxel anhydrous and Urinary Bladder Neoplasms

Article	Year
Sequential Gemcitabine plus Docetaxel Is the Standard Second-line Intravesical Therapy for Bacillus Calmette-Guérin-unresponsive Non-muscle invasive Bladder Cancer: Con. European urology focus, 2022, Volume: 8, Issue:4 Topics: BCG Vaccine; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms	2022
Sequential Gemcitabine plus Docetaxel Is the Standard Second-line Intravesical Therapy for BCG-unresponsive Non-muscle-invasive bladder cancer: Pro. European urology focus, 2022, Volume: 8, Issue:4 Topics: Administration, Intravesical; BCG Vaccine; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasm Invasiveness; Urinary Bladder Neoplasms	2022
Chronological transition in outcome of second-line treatment in patients with metastatic urothelial cancer after pembrolizumab approval: a multicenter retrospective analysis. International journal of clinical oncology, 2022, Volume: 27, Issue:1 Topics: Aged; Antibodies, Monoclonal, Humanized; Carcinoma, Transitional Cell; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Retrospective Studies; Urinary Bladder Neoplasms	2022
Response to Platinum-based Chemotherapy Rechallenge for Patients With Pembrolizumab-refractory Urothelial Carcinoma. Anticancer research, 2021, Volume: 41, Issue:11 Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Immune Checkpoint Inhibitors; Male; Middle Aged; Neutropenia; Paclitaxel; Retrospective Studies; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium	2021
Sequential Chemotherapy with Gemcitabine and Docetaxel: Breaking the Chains of bacillus Calmette-Guérin. The Journal of urology, 2022, Volume: 208, Issue:3 Topics: Adjuvants, Immunologic; Administration, Intravesical; BCG Vaccine; Carcinoma, Transitional Cell; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Mycobacterium bovis; Urinary Bladder Neoplasms	2022
Quality of Life, Efficacy, and Safety of Sequential Intravesical Gemcitabine + Docetaxel versus BCG for Non-Muscle Invasive Urinary Bladder Cancer: A Pilot Study. Urologia internationalis, 2022, Volume: 106, Issue:8 Topics: Administration, Intravesical; BCG Vaccine; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Pilot Projects; Prospective Studies; Quality of Life; Urinary Bladder Neoplasms	2022
Sequential Intravesical Valrubicin and Docetaxel for the Salvage Treatment of Non-Muscle-Invasive Bladder Cancer. The Journal of urology, 2022, Volume: 208, Issue:5 Topics: Adjuvants, Immunologic; Administration, Intravesical; BCG Vaccine; Carcinoma in Situ; Docetaxel; Doxorubicin; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Retrospective Studies; Salvage Therapy; Urinary Bladder Neoplasms	2022
Sequential Intravesical Gemcitabine and Docetaxel for bacillus Calmette-Guérin-Naïve High-Risk Nonmuscle-Invasive Bladder Cancer. The Journal of urology, 2022, Volume: 208, Issue:3 Topics: Adjuvants, Immunologic; Administration, Intravesical; Bacillus; BCG Vaccine; Carcinoma in Situ; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Retrospective Studies; Urinary Bladder Neoplasms	2022
Re: Sequential Intravesical Gemcitabine and Docetaxel for Bacillus Calmette-Guérin-naïve High-risk Nonmuscle-invasive Bladder Cancer. European urology, 2022, Volume: 82, Issue:6 Topics: Adjuvants, Immunologic; Administration, Intravesical; Bacillus; BCG Vaccine; Docetaxel; Gemcitabine; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms	2022
Long-term follow-up of sequential intravesical gemcitabine and docetaxel salvage therapy for non-muscle invasive bladder cancer. Urologic oncology, 2023, Volume: 41, Issue:3 Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; BCG Vaccine; Docetaxel; Follow-Up Studies; Gemcitabine; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Non-Muscle Invasive Bladder Neoplasms; Retrospective Studies; Salvage Therapy; Urinary Bladder Neoplasms	2023
Nonrisk-adapted Sequential Intravesical Gemcitabine and Docetaxel for Nonmuscle-invasive Bladder Cancer: The Time Is Now. The Journal of urology, 2023, Volume: 210, Issue:1 Topics: Administration, Intravesical; BCG Vaccine; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasm Invasiveness; Urinary Bladder Neoplasms	2023
Sequential intravesical gemcitabine-docetaxel vs. bacillus Calmette-Guerin (BCG) in the treatment of non-muscle invasive bladder cancer: A preliminary cost-effectiveness analysis. Urologic oncology, 2023, Volume: 41, Issue:9 Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; BCG Vaccine; Cost-Effectiveness Analysis; Docetaxel; Gemcitabine; Humans; Medicare; Neoplasm Invasiveness; Non-Muscle Invasive Bladder Neoplasms; United States; Urinary Bladder Neoplasms	2023
Background and Update for ECOG-ACRIN EA8212: A Randomized Phase 3 Trial of Intravesical Bacillus Calmette-Guérin (BCG) Versus Intravesical Docetaxel and Gemcitabine Treatment in BCG-naïve High-grade Non-muscle-invasive Bladder Cancer (BRIDGE). European urology focus, 2023, Volume: 9, Issue:4 Topics: Administration, Intravesical; BCG Vaccine; Clinical Trials, Phase III as Topic; Docetaxel; Gemcitabine; Humans; Non-Muscle Invasive Bladder Neoplasms; Randomized Controlled Trials as Topic; Urinary Bladder Neoplasms	2023
Sequential Intravesical Gemcitabine and Docetaxel is an Alternative to Bacillus Calmette-Guérin for the Treatment of Intermediate-risk Non-muscle-invasive Bladder Cancer. European urology oncology, 2023, Volume: 6, Issue:5 Topics: Administration, Intravesical; BCG Vaccine; Docetaxel; Gemcitabine; Humans; Non-Muscle Invasive Bladder Neoplasms; Retrospective Studies; Urinary Bladder Neoplasms	2023
Sequential intravesical gemcitabine/docetaxel provides a durable remission in recurrent high-risk NMIBC following BCG therapy. Urologic oncology, 2023, Volume: 41, Issue:11 Topics: Aged; BCG Vaccine; Docetaxel; Gemcitabine; Humans; Neoplasm Recurrence, Local; Non-Muscle Invasive Bladder Neoplasms; Prospective Studies; Retrospective Studies; Urinary Bladder Neoplasms	2023
An evaluation of monthly maintenance therapy among patients receiving intravesical combination gemcitabine/docetaxel for nonmuscle-invasive bladder cancer. Urologic oncology, 2020, Volume: 38, Issue:2 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Male; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms	2020
Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder Cancer. The Journal of urology, 2020, Volume: 203, Issue:5 Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biopsy; Canada; Cystoscopy; Deoxycytidine; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Gemcitabine; Humans; Immunosuppressive Agents; Male; Middle Aged; Neoplasm Invasiveness; Retrospective Studies; Survival Rate; Time Factors; Treatment Outcome; United States; Urinary Bladder Neoplasms	2020
A Novel Long Non-Coding RNA KMU15 Promotes Growth and Chemoresistance of Bladder Cancer. Clinical laboratory, 2019, Dec-01, Volume: 65, Issue:12 Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Mice, Inbred BALB C; Mice, Nude; RNA, Long Noncoding; Survival Analysis; Tumor Burden; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays	2019
Editorial Comment. The Journal of urology, 2020, Volume: 203, Issue:5 Topics: Deoxycytidine; Docetaxel; Gemcitabine; Health Facilities; Humans; Urinary Bladder Neoplasms	2020
Re: Multi-institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder Cancer. European urology, 2020, Volume: 78, Issue:3 Topics: Administration, Intravesical; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Urinary Bladder Neoplasms	2020
Aktuelle Urologie, 2020, Volume: 51, Issue:5 Topics: Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms	2020
Preclinical evaluation of a hypotonic docetaxel nanosuspension formulation for intravesical treatment of non-muscle-invasive bladder cancer. Drug delivery and translational research, 2021, Volume: 11, Issue:5 Topics: Administration, Intravesical; Animals; Docetaxel; Immunotherapy; Nanoparticles; Rats; Urinary Bladder Neoplasms	2021
Intravesical sequential gemcitabine and docetaxel versus bacillus calmette-guerin (BCG) plus interferon in patients with recurrent non-muscle invasive bladder cancer following a single induction course of BCG. Urologic oncology, 2022, Volume: 40, Issue:1 Topics: Adjuvants, Immunologic; Administration, Intravesical; Adult; Aged; Antineoplastic Agents; BCG Vaccine; Cohort Studies; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Induction Chemotherapy; Interferon alpha-2; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Treatment Outcome; Urinary Bladder Neoplasms	2022
Toward Better Predictions of Chemosensitivity: Comparative Study of Conventional and Simulated Chemosensitivity Tests for Bladder Cancer Cell Lines. Annals of laboratory medicine, 2017, Volume: 37, Issue:4 Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Docetaxel; Epirubicin; Gemcitabine; Humans; Mitomycin; Urinary Bladder Neoplasms	2017
Chemomechanically engineered 3D organotypic platforms of bladder cancer dormancy and reactivation. Biomaterials, 2017, Volume: 142 Topics: Antineoplastic Agents; Calcium; Cell Cycle; Cell Line, Tumor; Cell Shape; Docetaxel; Drug Resistance, Neoplasm; Endoplasmic Reticulum Stress; Humans; Mechanical Phenomena; Neoplasm Micrometastasis; Protein Biosynthesis; Taxoids; Tissue Engineering; Tumor Microenvironment; Urinary Bladder Neoplasms	2017
Intravesicular taxane-induced dermatotoxicity in a 78-year-old man with urothelial carcinoma and primary cutaneous anaplastic large cell lymphoma. Journal of cutaneous pathology, 2018, Volume: 45, Issue:6 Topics: Administration, Intravesical; Aged; Antineoplastic Agents; Carcinoma, Transitional Cell; Docetaxel; Drug Eruptions; Humans; Lymphoma, Primary Cutaneous Anaplastic Large Cell; Male; Neoplasms, Multiple Primary; Taxoids; Urinary Bladder Neoplasms	2018
Preclinical analyses of intravesical chemotherapy for prevention of bladder cancer progression. Oncotarget, 2013, Volume: 4, Issue:2 Topics: Administration, Intravesical; Animals; Antineoplastic Agents; Cycloleucine; Deoxycytidine; Disease Models, Animal; Disease Progression; Docetaxel; Drug Screening Assays, Antitumor; Female; Gemcitabine; Mice; Mice, Inbred C57BL; Random Allocation; Taxoids; Treatment Outcome; Urinary Bladder Neoplasms	2013
Do patients with metastatic urothelial carcinoma benefit from docetaxel as second-line chemotherapy? Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2014, Volume: 16, Issue:1 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Transitional Cell; Disease-Free Survival; Docetaxel; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Retrospective Studies; Salvage Therapy; Taxoids; Urinary Bladder Neoplasms	2014
Regression of choroidal neovascularization in response to systemic chemotherapy for cancer. Canadian journal of ophthalmology. Journal canadien d'ophtalmologie, 2013, Volume: 48, Issue:4 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Choroidal Neovascularization; Cisplatin; Deoxycytidine; Docetaxel; Fatal Outcome; Fluorescein Angiography; Gemcitabine; Humans; Male; Remission Induction; Taxoids; Tomography, Optical Coherence; Urethral Neoplasms; Urinary Bladder Neoplasms	2013
The inhibitory and apoptotic effects of docetaxel-loaded mesoporous magnetic colloidal nanocrystal clusters on bladder cancer T24 cells in vitro. Journal of biomedical nanotechnology, 2014, Volume: 10, Issue:3 Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Colloids; Docetaxel; Drug Carriers; Drug Evaluation, Preclinical; Humans; Magnetite Nanoparticles; Nanoparticles; Polyglutamic Acid; Porosity; Taxoids; Urinary Bladder Neoplasms	2014
Carboplatin-based combination chemotherapy for elderly patients with advanced bladder cancer. International journal of clinical oncology, 2015, Volume: 20, Issue:2 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cystectomy; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lymphatic Metastasis; Male; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome; Urinary Bladder Neoplasms	2015
Mucoadhesive polyacrylamide nanogel as a potential hydrophobic drug carrier for intravesical bladder cancer therapy. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2015, May-25, Volume: 72 Topics: Acrylic Resins; Adhesiveness; Animals; Antineoplastic Agents; Cell Line, Tumor; Docetaxel; Drug Carriers; Drug Liberation; Gels; Hydrophobic and Hydrophilic Interactions; Mucins; Nanoparticles; Swine; Taxoids; Urinary Bladder; Urinary Bladder Neoplasms; Urothelium	2015
Retrospective review of the incidence of monitoring blood glucose levels in patients receiving corticosteroids with systemic anticancer therapy. Annals of palliative medicine, 2015, Volume: 4, Issue:2 Topics: Aged; Antineoplastic Agents; Blood Glucose; Comorbidity; Dexamethasone; Diabetes Complications; Diabetes Mellitus; Docetaxel; Drug Therapy, Combination; Glucocorticoids; Humans; Hyperglycemia; Male; Monitoring, Physiologic; Ontario; Prednisone; Prostatic Neoplasms; Retrospective Studies; Taxoids; Urinary Bladder Neoplasms; Urogenital Neoplasms	2015
Bladder and gastric metastases from lung adenocarcinoma harboring codon 13 KRAS mutation: a case report with unusual clinical outcome. Tumori, 2015, Sep-09, Volume: 101, Issue:5 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Codon; Cystoscopy; Disease Progression; Docetaxel; Fatal Outcome; Female; Gastroscopy; Humans; Lung Neoplasms; Mutation; Neoplasms, Second Primary; Pemetrexed; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Salvage Therapy; Stomach Neoplasms; Taxoids; Urinary Bladder Neoplasms	2015
Carotid artery inflammation associated with gemcitabine-based therapy: a special report. Future oncology (London, England), 2015, Volume: 11, Issue:14 Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Arteritis; Carotid Arteries; Carotid Artery Diseases; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Male; Middle Aged; Taxoids; Tomography, X-Ray Computed; Urinary Bladder Neoplasms; Vasculitis	2015
Effectiveness of capecitabine with or without docetaxel therapy for the treatment of patients with advanced urothelial carcinoma: a single-institution experience. Oncotarget, 2016, Sep-27, Volume: 7, Issue:39 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Carcinoma, Transitional Cell; Disease-Free Survival; Docetaxel; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Palliative Care; Retrospective Studies; Taxoids; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium	2016
The novel use of intravesical docetaxel for the treatment of non-muscle invasive bladder cancer refractory to BCG therapy: a single institution experience. World journal of urology, 2009, Volume: 27, Issue:3 Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; BCG Vaccine; Docetaxel; Female; Humans; Male; Middle Aged; Neoplasm Invasiveness; Retrospective Studies; Taxoids; Treatment Failure; Urinary Bladder Neoplasms	2009
Editorial comment. Urology, 2010, Volume: 75, Issue:1 Topics: Administration, Intravesical; Antineoplastic Agents; Carcinoma, Transitional Cell; Docetaxel; Humans; Taxoids; Urinary Bladder Neoplasms	2010
The uptake of paclitaxel and docetaxel into ex vivo porcine bladder tissue from polymeric micelle formulations. Cancer chemotherapy and pharmacology, 2011, Volume: 68, Issue:2 Topics: Administration, Intravesical; Animals; Antineoplastic Agents; Biological Transport; Docetaxel; Drug Carriers; Drug Compounding; Glycerol; In Vitro Techniques; Male; Micelles; Nanoparticles; Paclitaxel; Pharmaceutical Vehicles; Polyesters; Polyethylene Glycols; Polysorbates; Swine; Taxoids; Tissue Distribution; Urinary Bladder; Urinary Bladder Neoplasms	2011
In vitro and in vivo evaluation of intravesical docetaxel loaded hydrophobically derivatized hyperbranched polyglycerols in an orthotopic model of bladder cancer. Biomacromolecules, 2011, Apr-11, Volume: 12, Issue:4 Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Proliferation; Chromatography, Gel; Disease Models, Animal; Docetaxel; In Vitro Techniques; Magnetic Resonance Spectroscopy; Mice; Microscopy, Confocal; Microscopy, Fluorescence; Particle Size; Taxoids; Urinary Bladder Neoplasms	2011
In vivo evaluation of mucoadhesive nanoparticulate docetaxel for intravesical treatment of non-muscle-invasive bladder cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, May-01, Volume: 17, Issue:9 Topics: Adhesiveness; Administration, Intravesical; Animals; Antineoplastic Agents; Carcinoma; Cell Line, Tumor; Docetaxel; Female; Humans; Mice; Mice, Nude; Mucous Membrane; Muscle, Smooth; Nanoparticles; Neoplasm Invasiveness; Taxoids; Treatment Outcome; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays	2011
Pazopanib synergizes with docetaxel in the treatment of bladder cancer cells. Urology, 2011, Volume: 78, Issue:1 Topics: Antineoplastic Agents; Docetaxel; Drug Synergism; Drug Therapy, Combination; Humans; Indazoles; Pyrimidines; Sulfonamides; Taxoids; Tumor Cells, Cultured; Urinary Bladder Neoplasms	2011
Successful treatment of metastatic extramammary Paget's disease with S-1 and docetaxel combination chemotherapy. The Journal of dermatology, 2011, Volume: 38, Issue:10 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Drug Combinations; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Oxonic Acid; Paget Disease, Extramammary; Skin Neoplasms; Taxoids; Tegafur; Tomography, X-Ray Computed; Urinary Bladder Neoplasms	2011
Tissue uptake of docetaxel loaded hydrophobically derivatized hyperbranched polyglycerols and their effects on the morphology of the bladder urothelium. Biomaterials, 2012, Volume: 33, Issue:2 Topics: Animals; Chemistry, Pharmaceutical; Disease Models, Animal; Docetaxel; Drug Delivery Systems; Female; Glycerol; Hydrophobic and Hydrophilic Interactions; Male; Mice; Mice, Nude; Microscopy, Electron, Scanning; Microscopy, Electron, Transmission; Nanoparticles; Polymers; Swine; Taxoids; Urinary Bladder; Urinary Bladder Neoplasms; Urothelium	2012
5-azacytidine reverses drug resistance in bladder cancer cells. Anticancer research, 2011, Volume: 31, Issue:11 Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azacitidine; Blotting, Western; CARD Signaling Adaptor Proteins; Cell Cycle; Cell Cycle Proteins; Cisplatin; Cytoskeletal Proteins; DNA Methylation; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; Humans; Real-Time Polymerase Chain Reaction; RNA, Messenger; Taxoids; Tumor Cells, Cultured; Tumor Suppressor Proteins; Urinary Bladder Neoplasms	2011
Long-term survival outcomes with intravesical docetaxel for recurrent nonmuscle invasive bladder cancer after previous bacillus Calmette-Guérin therapy. The Journal of urology, 2013, Volume: 189, Issue:3 Topics: Adjuvants, Immunologic; Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; BCG Vaccine; Docetaxel; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Prospective Studies; Survival Rate; Taxoids; Time Factors; Treatment Outcome; United States; Urinary Bladder; Urinary Bladder Neoplasms	2013
[Updates on gemcitabine at the American Society of Clinical Oncology congress (ASCO, 2002) ]. Bulletin du cancer, 2002, Volume: 89 Spec No Topics: Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Enzyme Inhibitors; Female; Gemcitabine; Glutamates; Guanine; Humans; Immunotherapy; Lung Neoplasms; Mitomycins; Multicenter Studies as Topic; Neoplasms, Unknown Primary; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Pemetrexed; Radiotherapy; Remission Induction; Taxoids; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine; Vinorelbine	2002
Docetaxel enhances the therapeutic effect of the angiogenesis inhibitor TNP-470 (AGM-1470) in metastatic human transitional cell carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Volume: 9, Issue:2 Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Carcinoma, Transitional Cell; Cyclohexanes; Docetaxel; Drug Synergism; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Neovascularization, Pathologic; O-(Chloroacetylcarbamoyl)fumagillol; Paclitaxel; Sesquiterpenes; Taxoids; Time Factors; Transplantation, Heterologous; Urinary Bladder Neoplasms	2003
Gemcitabine plus carboplatin; and gemcitabine, docetaxel, and carboplatin combined chemotherapy regimens in patients with metastatic urothelial carcinoma previously treated with a platinum-based regimen: preliminary report. International journal of clinical oncology, 2004, Volume: 9, Issue:2 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pilot Projects; Taxoids; Treatment Outcome; Ureteral Neoplasms; Urinary Bladder Neoplasms	2004
[Multidisciplinary treatment for advanced bladder cancer--a case report]. Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Transitional Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Doxorubicin; Female; Humans; Infusion Pumps, Implantable; Infusions, Intra-Arterial; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Quality of Life; Taxoids; Urinary Bladder Neoplasms	2004
[Active chemotherapy with gemcitabine, carboplatin and docetaxel for three patients with MVAC-resistant liver metastasis of urothelial carcinoma]. Hinyokika kiyo. Acta urologica Japonica, 2004, Volume: 50, Issue:4 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Docetaxel; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Gemcitabine; Humans; Kidney Neoplasms; Liver Neoplasms; Male; Methotrexate; Middle Aged; Taxoids; Urinary Bladder Neoplasms; Vinblastine	2004
Neoadjuvant chemotherapy with docetaxel and cisplatin in patients with high-risk resectable bladder carcinoma: long term results. European urology, 2004, Volume: 46, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Docetaxel; Feasibility Studies; Female; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Remission Induction; Survival Analysis; Taxoids; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms	2004
Effect of combination therapy with a novel bisphosphonate, minodronate (YM529), and docetaxel on a model of bone metastasis by human transitional cell carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Sep-15, Volume: 11, Issue:18 Topics: Acid Phosphatase; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Neoplasms; Bone Resorption; Carcinoma, Transitional Cell; Cell Line; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Docetaxel; Dose-Response Relationship, Drug; Humans; Imidazoles; Immunohistochemistry; In Situ Nick-End Labeling; Isoenzymes; Mice; Mice, Inbred BALB C; Mice, Nude; Osteoblasts; Proliferating Cell Nuclear Antigen; Tartrate-Resistant Acid Phosphatase; Taxoids; Tibia; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays	2005
CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor--armed oncolytic adenovirus for the treatment of bladder cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Jan-01, Volume: 12, Issue:1 Topics: Adenoviridae; Adenovirus E1A Proteins; Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Transitional Cell; Cell Line, Tumor; Docetaxel; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Immunohistochemistry; Mice; Mice, Nude; Oncolytic Virotherapy; Oncolytic Viruses; Retinoblastoma Protein; Reverse Transcriptase Polymerase Chain Reaction; Taxoids; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays	2006
[A case of hormone-refractory prostate cancer (HRPC) with tumor fever responding to docetaxel plus prednisolone therapy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:6 Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Fever; Gonadotropin-Releasing Hormone; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Neoplasm Invasiveness; Prednisolone; Prostatic Neoplasms; Taxoids; Urinary Bladder Neoplasms	2006
Schedule dependent efficacy of gefitinib and docetaxel for bladder cancer. The Journal of urology, 2006, Volume: 176, Issue:2 Topics: Animals; Antineoplastic Agents; Carcinoma, Transitional Cell; Docetaxel; Drug Administration Schedule; Gefitinib; Humans; Male; Mice; Mice, Inbred BALB C; Quinazolines; Taxoids; Tumor Cells, Cultured; Urinary Bladder Neoplasms	2006
[Optimizing treatment of advanced urologic malignancies]. Der Urologe. Ausg. A, 2007, Volume: 46, Issue:9 Topics: Carcinoma, Transitional Cell; Docetaxel; Drug Resistance, Neoplasm; Education, Medical, Graduate; Gene Expression Profiling; Humans; Lymphatic Metastasis; Male; Neoplasm Staging; Neoplasms, Germ Cell and Embryonal; Palliative Care; Prognosis; Prostatic Neoplasms; Quality Assurance, Health Care; Research; Taxoids; Testicular Neoplasms; Transurethral Resection of Prostate; Urinary Bladder Neoplasms; Urologic Neoplasms; Urology	2007
Locally advanced leiomyosarcoma of the urinary bladder: near-complete pathologic response to neoadjuvant gemcitabine and docetaxel. Anti-cancer drugs, 2007, Volume: 18, Issue:6 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Docetaxel; Gemcitabine; Humans; Leiomyosarcoma; Male; Neoadjuvant Therapy; Neoplasm Invasiveness; Taxoids; Urinary Bladder Neoplasms	2007
[Effect of the association of antimitotic agents on cell lines of human adenocarcinoma]. Bulletin du cancer, 1994, Volume: 81, Issue:10 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carbamates; Colonic Neoplasms; Docetaxel; Humans; Paclitaxel; Pyrazines; Pyridines; Skin Neoplasms; Taxoids; Tumor Cells, Cultured; Urinary Bladder Neoplasms; Vinblastine; Vinorelbine	1994
Taxol and taxotere in bladder cancer: in vitro activity and urine stability. Cancer chemotherapy and pharmacology, 1994, Volume: 33, Issue:6 Topics: Antineoplastic Agents, Phytogenic; Cell Division; Chromatography, High Pressure Liquid; Docetaxel; Humans; Paclitaxel; Taxoids; Tumor Cells, Cultured; Tumor Stem Cell Assay; Urinary Bladder Neoplasms	1994
Overexpression of Bcl-2 regulates sodium butyrate- and/or docetaxel-induced apoptosis in human bladder cancer cells both in vitro and in vivo. International journal of cancer, 2001, Jul-01, Volume: 93, Issue:1 Topics: Amides; Animals; Antineoplastic Agents; Apoptosis; Butyrates; Cell Division; Docetaxel; Female; Genes, bcl-2; Humans; Mice; Mice, Nude; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Taxoids; Transfection; Transplantation, Heterologous; Tumor Cells, Cultured; Urinary Bladder Neoplasms	2001
Change in pharmacokinetic and pharmacodynamic behavior of gemcitabine in human tumor xenografts upon entrapment in vesicular phospholipid gels. Cancer chemotherapy and pharmacology, 2002, Volume: 49, Issue:5 Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Deoxycytidine; Docetaxel; Gels; Gemcitabine; Half-Life; Humans; Liposomes; Mice; Mice, Nude; Neoplasm Transplantation; Paclitaxel; Phospholipids; Sarcoma; Taxoids; Tissue Distribution; Transplantation, Heterologous; Urinary Bladder Neoplasms; Vindesine	2002
Identification of human uroplakin II promoter and its use in the construction of CG8840, a urothelium-specific adenovirus variant that eliminates established bladder tumors in combination with docetaxel. Cancer research, 2002, Jul-01, Volume: 62, Issue:13 Topics: Adenovirus E1B Proteins; Adenoviruses, Human; Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Transitional Cell; Combined Modality Therapy; Cytopathogenic Effect, Viral; Docetaxel; Drug Synergism; Gene Deletion; Genes, Regulator; Humans; Membrane Proteins; Mice; Mice, Inbred BALB C; Mice, Nude; Paclitaxel; Promoter Regions, Genetic; Taxoids; Urinary Bladder Neoplasms; Uroplakin II; Virus Replication; Xenograft Model Antitumor Assays	2002